At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
DNA Ginkgo Bioworks Holdings Inc.
Market Closed 09-18 16:00:00 EDT
7.88
+0.04
+0.51%
盘后7.88
+0.00-0.01%
19:57 EDT
High7.98Low7.50Vol1.76M
Open7.83D1 Closing7.84Amplitude6.19%
Mkt Cap530.64MTradable Cap393.00MTotal Shares67.34M
T/O13.76MT/O Rate3.54%Tradable Shares49.87M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Ginkgo Bioworks Director Christian O. Henry Disposes of 5,000 Common Shares Worth $35,405
Reuters  ·  09-17 04:07
Ginkgo Bioworks Director Christian O. Henry Disposes of 5,000 Common Shares Worth $35,405
Ginkgo Datapoints Announces Partnership with Tunelab to Close the Gap Between AI Models and Lab Data
THOMSON REUTERS  ·  09-16 21:52
Ginkgo Datapoints Announces Partnership with Tunelab to Close the Gap Between AI Models and Lab Data
Ginkgo Datapoints Partners with Lilly TuneLab on AI-Driven Drug Discovery Lab Data Generation
Reuters  ·  09-16 20:05
Ginkgo Datapoints Partners with Lilly TuneLab on AI-Driven Drug Discovery Lab Data Generation
Ginkgo Bioworks Holdings, - Awarded Subcontract for up to $17.50 Mln Under Arpa-H Give Program
THOMSON REUTERS  ·  09-10
Ginkgo Bioworks Holdings, - Awarded Subcontract for up to $17.50 Mln Under Arpa-H Give Program
Ginkgo Bioworks Joins Waterfall Scientific-Led ARPA-H Consortium to Build Autonomous RNA Drug Manufacturing System
Reuters  ·  09-10
Ginkgo Bioworks Joins Waterfall Scientific-Led ARPA-H Consortium to Build Autonomous RNA Drug Manufacturing System
Press Release: Candel Therapeutics Appoints Martine Zimmermann, PharmD, to Its Board of Directors
Dow Jones  ·  09-10
Press Release: Candel Therapeutics Appoints Martine Zimmermann, PharmD, to Its Board of Directors
Arm's Haas: AI Could Cure Cancer In Our Lifetime — If The Industry Can Build Enough Chips
AI Industry Frontlines  ·  09-08
Arm's Haas: AI Could Cure Cancer In Our Lifetime — If The Industry Can Build Enough Chips
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ginkgo Bioworks Holdings (DNA) and Vericel (VCEL)
TIPRANKS  ·  09-04
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ginkgo Bioworks Holdings (DNA) and Vericel (VCEL)
Ginkgo Bioworks Holdings Price Target Maintained with a $5.00/Share by BTIG
Dow Jones  ·  09-04
Ginkgo Bioworks Holdings Price Target Maintained with a $5.00/Share by BTIG
4basebio Strikes Genezen Pact to Advance Synthetic DNA for Viral Vector Manufacturing
TIPRANKS  ·  08-26
4basebio Strikes Genezen Pact to Advance Synthetic DNA for Viral Vector Manufacturing
WuXi AppTec Contains Cyber Breach in DNA-Encoded Library Platform
TIPRANKS  ·  08-24
WuXi AppTec Contains Cyber Breach in DNA-Encoded Library Platform
DNA X Q2 EPS $(0.91) Up From $(14.15) YoY
Benzinga Earnings  ·  08-20
DNA X Q2 EPS $(0.91) Up From $(14.15) YoY
DNA X, Inc. Reports Second Quarter 2026 Financial Results
GlobeNewswire  ·  08-20
DNA X, Inc. Reports Second Quarter 2026 Financial Results
Ginkgo Bioworks Holdings Cut to Hold from Buy by TD Cowen
Dow Jones  ·  08-08
Ginkgo Bioworks Holdings Cut to Hold from Buy by TD Cowen
Ginkgo Bioworks Holdings, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-07
Ginkgo Bioworks Holdings, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ginkgo Bioworks Holdings (DNA), Exelixis (EXEL) and Editas Medicine (EDIT)
TIPRANKS  ·  08-06
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ginkgo Bioworks Holdings (DNA), Exelixis (EXEL) and Editas Medicine (EDIT)
Ginkgo Bioworks Q2 FY26 GAAP Net Loss Widens to $57 Million; Revenue Drops 48% to $20 Million
Reuters  ·  08-06
Ginkgo Bioworks Q2 FY26 GAAP Net Loss Widens to $57 Million; Revenue Drops 48% to $20 Million
Ginkgo Bioworks Expands Autonomous Lab Network to Caltech, MIT, Maryland and Northwestern
Reuters  ·  08-05
Ginkgo Bioworks Expands Autonomous Lab Network to Caltech, MIT, Maryland and Northwestern
Ginkgo Bioworks Holdings Inc Expected to Post a Loss of 91 Cents a Share - Earnings Preview
Reuters  ·  08-04
Ginkgo Bioworks Holdings Inc Expected to Post a Loss of 91 Cents a Share - Earnings Preview
Ginkgo Bioworks Partners with Acies Bio to License Aspergillus Niger Strains for Protein Production
Reuters  ·  08-03
Ginkgo Bioworks Partners with Acies Bio to License Aspergillus Niger Strains for Protein Production

Introduction

Company Name.
Ginkgo Bioworks Holdings Inc.
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Issue price:
--